Commercialisation of the bio-therapeutic resolution agent HYPER-DS-sIL-6R. (360G-Wellcome-079044_Z_06_A)

£109,851

The increased incidence of antibiotic resistant bacterial strains such as MRSA and VRSAover the past few years has identified the necessity for development of alternative therapeutic strategies. Professor Nicholas Topley and Dr Simon Jones at the University of Wales have been awarded translational funding to further develop a therapeutic to supplement the body's existing defence system to help clear various types of bacterial infection.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 109851
Applicant Surname Topley
Approval Committee Technology Transfer Challenge Committee
Award Date 2009-06-08T00:00:00+00:00
Financial Year 2008/09
Grant Programme: Title Translation Award
Internal ID 079044/Z/06/A
Lead Applicant Prof Nicholas Topley
Partnership Value 109851
Planned Dates: End Date 2009-12-31T00:00:00+00:00
Planned Dates: Start Date 2007-01-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Wales